India Pneumococcal Vaccine Market to Grow with a CAGR of 9.85% through 2030
Rising Geriatric Population and Expanding Healthcare
Infrastructure is expected to drive the India Pneumococcal Vaccine Market
growth in the forecast period, 2026-2030
According to
TechSci Research report, “India Pneumococcal Vaccine Market – By Region,
Competition, Forecast & Opportunities, 2030F”, the India Pneumococcal
Vaccine Market stood at USD 113.30 Million in 2024 and is anticipated to grow
with a CAGR of 9.85% in the forecast period, 2026-2030.
The increasing
emphasis on research and development (R\&D) is a key driver of growth in
India’s pneumococcal vaccine market, enabling innovation in formulations and
improving both efficacy and accessibility. With rising incidences of
pneumococcal infections and growing bacterial resistance, Indian pharmaceutical
companies are prioritizing next-generation vaccine development to meet evolving
public health needs.
Leading domestic
manufacturers such as Serum Institute of India (SII) and Bharat Biotech are
investing heavily in R&D to deliver high-efficacy, cost-efficient vaccines
suited to local epidemiological profiles. The introduction of SII’s Pneumosil
has significantly reduced reliance on high-cost imports while boosting national
immunization efforts. Meanwhile, new offerings like Abbott’s 14-valent
pneumococcal conjugate vaccine highlight how R\&D is extending serotype
coverage to provide broader protection.
Strategic
collaborations and technology transfers between Indian manufacturers and global
health bodies such as WHO, Gavi, and UNICEF are accelerating development
timelines. These alliances support faster clinical validation, optimize cold
chain logistics, and help scale affordable vaccine solutions for mass
immunization programs across the country.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "India Pneumococcal Vaccine Market”
The India
Pneumococcal Vaccine Market is segmented into vaccine type, end use, regional
distribution, and company.
Based on its end
use, Public Sector have emerged as the dominating segment in the India
Pneumococcal Vaccine Market in 2024. This dominance is primarily driven by
government-led immunization programs, large-scale procurement, and
affordability initiatives aimed at ensuring widespread vaccine coverage,
particularly among infants and vulnerable populations. The Universal
Immunization Programme (UIP) has been instrumental in boosting the demand for
pneumococcal vaccines in the public sector, providing free or subsidized
vaccination through government hospitals, primary health centers (PHCs), and
community health centers (CHCs).
Organizations
like WHO, Gavi, and UNICEF have collaborated with the Indian government to
enhance vaccine accessibility, further strengthening the public sector's
dominance. The introduction of domestically manufactured cost-effective
vaccines like Serum Institute of India's Pneumosil has made PCV more affordable
for large-scale public distribution. While the private sector caters to urban,
high-income populations through hospitals and clinics, its contribution remains
secondary due to higher vaccine costs and out-of-pocket expenditures. With the
government’s continued focus on expanding immunization coverage and reducing
the burden of pneumococcal diseases, the public sector is expected to maintain
its leading position in the coming years.
Based on Region,
East India have emerged as the fastest growing region in the India Pneumococcal
Vaccine Market in 2024. This rapid growth is driven by increasing government
immunization efforts, rising awareness about pneumococcal diseases, and
improved healthcare access in rural areas. States like West Bengal, Bihar,
Odisha, and Jharkhand have witnessed significant expansion in vaccination
programs, particularly under the Universal Immunization Programme (UIP). The
region has a high burden of pneumonia-related child mortality, prompting
targeted intervention strategies. Additionally, infrastructure improvements,
expanded cold chain facilities, and growing penetration of private healthcare
providers have further fueled vaccine uptake.
Major companies
operating in India Pneumococcal Vaccine Market are:
- Pfizer Inc.
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Serum Institute of India Pvt. Ltd.
- Panacea Biotec Limited
- Sanofi SA
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The increasing participation
of private healthcare providers, pharmaceutical companies, and corporate-backed
immunization programs is playing a crucial role in expanding access to
pneumococcal vaccines across India. With a rising preference for advanced
healthcare services, private hospitals, clinics, and diagnostic centers are
integrating premium vaccination services, making immunization more accessible
to urban and semi-urban populations.,” said Mr. Karan Chechi, Research Director
of TechSci Research, a research-based management consulting firm.
“India
Pneumococcal Vaccine Market, By Vaccine Type (Pneumococcal Conjugate Vaccine,
Pneumococcal Polysaccharide Vaccine), By End Use (Public Sector, Private
Sector), By Region, Competition, Forecast & Opportunities,
2020-2030F”, has evaluated the future growth potential of India
Pneumococcal Vaccine Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in India
Pneumococcal Vaccine Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com